{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:53:31Z","timestamp":1785365611876,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-82445-0","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T23:42:37Z","timestamp":1735342957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A comparation of three different anti-VEGF drugs in development of persistent avascular retina in premature children"],"prefix":"10.1038","volume":"14","author":[{"given":"Ay\u015fe Cengiz","family":"\u00dcnal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melih","family":"Ak\u0131dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammet Kaz\u0131m","family":"Erol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"key":"82445_CR1","doi-asserted-by":"publisher","unstructured":"[No authors listed.] An international classification of retinopathy of prematurity. The Committee for the classification of retinopathy of prematurity. Arch. Ophthalmol. 102, 1130\u20131134. https:\/\/doi.org\/10.1001\/archopht.1984.01040030908011 (1984).","DOI":"10.1001\/archopht.1984.01040030908011"},{"key":"82445_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1001\/archopht.118.5.645","volume":"118","author":"MX Repka","year":"2000","unstructured":"Repka, M. X. et al. Involution of retinopathy of prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch. Ophthalmol. 118, 645\u2013649. https:\/\/doi.org\/10.1001\/archopht.118.5.645 (2000).","journal-title":"Arch. Ophthalmol."},{"key":"82445_CR3","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","volume":"245","author":"EJ Chung","year":"2007","unstructured":"Chung, E. J. et al. Combination of laser photocoagulation and intravitreal bevacizumab (avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch. Clin. Exp. Ophthalmol. 245, 1727\u20131730. https:\/\/doi.org\/10.1007\/s00417-007-0661-y (2007).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"82445_CR4","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.oret.2022.02.006","volume":"6","author":"BW Fleck","year":"2022","unstructured":"Fleck, B. W. et al. Time course of retinopathy of prematurity regression and reactivation after treatment with ranibizumab or laser in the RAINBOW Trial. Ophthalmol. Retin 6, 628\u2013637. https:\/\/doi.org\/10.1016\/j.oret.2022.02.006 (2022).","journal-title":"Ophthalmol. Retin"},{"key":"82445_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/nejmoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner, H. A. et al. Efficacy of intravitreal bevacizumab for stage 3\u2009+\u2009retinopathy of prematurity. N Engl. J. Med. 364, 603\u2013615. https:\/\/doi.org\/10.1056\/nejmoa1007374 (2011).","journal-title":"N Engl. J. Med."},{"key":"82445_CR6","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3928\/23258160-20200228-07","volume":"51","author":"D Lepore","year":"2020","unstructured":"Lepore, D. et al. Functional and morphologic findings at four years after intravitreal bevacizumab or laser for type 1 ROP. Ophthalmic Surg. Lasers Imaging Retina 51, 180\u2013186. https:\/\/doi.org\/10.3928\/23258160-20200228-07 (2020).","journal-title":"Ophthalmic Surg. Lasers Imaging Retina"},{"key":"82445_CR7","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","volume":"135","author":"DK Wallace","year":"2017","unstructured":"Wallace, D. K. et al. Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study. JAMA Ophthalmol. 135, 654\u2013656. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.1055 (2017).","journal-title":"JAMA Ophthalmol."},{"key":"82445_CR8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ophtha.2023.09.032","volume":"131","author":"H Robles-Holmes","year":"2024","unstructured":"Robles-Holmes, H. et al. Imaging features associated with persistent avascular retina in retinopathy of prematurity. Ophthalmology 131, 122\u2013124. https:\/\/doi.org\/10.1016\/j.ophtha.2023.09.032 (2024).","journal-title":"Ophthalmology"},{"key":"82445_CR9","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","volume":"128","author":"MF Chiang","year":"2021","unstructured":"Chiang, M. F. et al. International classification of retinopathy of prematurity, third edition. Ophthalmology 128, e51\u2013e68. https:\/\/doi.org\/10.1016\/j.ophtha.2021.05.031 (2021).","journal-title":"Ophthalmology"},{"key":"82445_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1136\/bjo.2003.022962","volume":"88","author":"A Tufail","year":"2004","unstructured":"Tufail, A. et al. Late onset vitreoretinal complications of regressed retinopathy of prematurity. Br. J. Ophthalmol. 88, 243\u2013246. https:\/\/doi.org\/10.1136\/bjo.2003.022962 (2004).","journal-title":"Br. J. Ophthalmol."},{"key":"82445_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaapos.2021.09.004","volume":"26","author":"AM Hanif","year":"2022","unstructured":"Hanif, A. M. et al. Prevalence of persistent avascular retina in untreated children with a history of retinopathy of prematurity screening. J. AAPOS 26, 29\u201331. https:\/\/doi.org\/10.1016\/j.jaapos.2021.09.004 (2022).","journal-title":"J. AAPOS"},{"key":"82445_CR12","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.oret.2017.11.012","volume":"2","author":"O Ar\u00e1mbulo","year":"2018","unstructured":"Ar\u00e1mbulo, O. et al. Analysis of the recurrence of plus disease after intravitreal ranibizumab as a primary monotherapy for severe retinopathy of prematurity. Ophthalmol. Retin 2, 858\u2013863. https:\/\/doi.org\/10.1016\/j.oret.2017.11.012 (2018).","journal-title":"Ophthalmol. Retin"},{"key":"82445_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000449530","volume":"236","author":"E Alyama\u00e7 Sukgen","year":"2016","unstructured":"Alyama\u00e7 Sukgen, E. et al. The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity: a comparison study between ranibizumab and bevacizumab. Ophthalmologica 236, 139\u2013147. https:\/\/doi.org\/10.1159\/000449530 (2016).","journal-title":"Ophthalmologica"},{"key":"82445_CR14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.2147\/opth.s11864","volume":"30","author":"M Kernt","year":"2010","unstructured":"Kernt, M. et al. Choroidal pigmented lesions imaged by ultra-wide-field scanning laser ophthalmoscopy with two laser wavelengths (optomap). Clin. Ophthalmol. 30, 829\u2013836. https:\/\/doi.org\/10.2147\/opth.s11864 (2010).","journal-title":"Clin. Ophthalmol."},{"key":"82445_CR15","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3928\/23258160-20231019-03","volume":"54","author":"PE Stanga","year":"2023","unstructured":"Stanga, P. E. et al. New 200\u00b0 single-capture color red-green-blue ultra-widefield retinal imaging technology: first clinical experience. Ophthalmic Surg. Lasers Imaging Retina 54, 714\u2013718. https:\/\/doi.org\/10.3928\/23258160-20231019-03 (2023).","journal-title":"Ophthalmic Surg. Lasers Imaging Retina"},{"key":"82445_CR16","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1364\/BOE.406299","volume":"11","author":"D Toslak","year":"2020","unstructured":"Toslak, D. et al. Portable ultra-widefield fundus camera for multispectral imaging of the retina and choroid. Biomed. Opt. Express 11, 6281\u20136292. https:\/\/doi.org\/10.1364\/BOE.406299 (2020).","journal-title":"Biomed. Opt. Express"},{"key":"82445_CR17","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3390\/life12070973","volume":"12","author":"S Biswas","year":"2022","unstructured":"Biswas, S. et al. Which color channel is better for diagnosing retinal diseases automatically in color fundus photographs? Life (Basel) 12, 973. https:\/\/doi.org\/10.3390\/life12070973 (2022).","journal-title":"Life (Basel)"},{"key":"82445_CR18","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00417-022-05855-8","volume":"261","author":"JY Moon","year":"2023","unstructured":"Moon, J. Y. et al. Visualization of retinal breaks on ultra-widefield fundus imaging using a digital green filter. Graefes Arch. Clin. Exp. Ophthalmol. 261, 935\u2013940. https:\/\/doi.org\/10.1007\/s00417-022-05855-8 (2023).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"82445_CR19","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.oret.2019.12.015","volume":"4","author":"AE Hamad","year":"2020","unstructured":"Hamad, A. E. et al. Late-onset retinal findings and complications in untreated retinopathy of prematurity. Ophthalmol. Retin 4, 602\u2013612. https:\/\/doi.org\/10.1016\/j.oret.2019.12.015 (2020).","journal-title":"Ophthalmol. Retin"},{"key":"82445_CR20","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1097\/iae.0b013e31820d3f70","volume":"31","author":"LY Ho","year":"2011","unstructured":"Ho, L. Y. et al. Management of avascular peripheral retina in older prematurely born infants. Retina 31, 1248\u20131253. https:\/\/doi.org\/10.1097\/iae.0b013e31820d3f70 (2011).","journal-title":"Retina"},{"key":"82445_CR21","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3928\/23258160-20180628-05","volume":"49","author":"CC Warren","year":"2018","unstructured":"Warren, C. C. et al. Findings in persistent retinopathy of prematurity. Ophthalmic Surg. Lasers Imaging Retina. 49, 497\u2013503. https:\/\/doi.org\/10.3928\/23258160-20180628-05 (2018).","journal-title":"Ophthalmic Surg. Lasers Imaging Retina"},{"key":"82445_CR22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.18240\/ijo.2019.09.22","volume":"12","author":"Y Cheng","year":"2019","unstructured":"Cheng, Y. et al. Fluorescein angiography of retinal vascular involution after intravitreal injection of ranibizumab for retinopathy of prematurity. Int. J. Ophthalmol. 12, 79\u201382. https:\/\/doi.org\/10.18240%2Fijo.2019.01.12 (2019).","journal-title":"Int. J. Ophthalmol."},{"key":"82445_CR23","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","volume":"98","author":"SG Tahija","year":"2014","unstructured":"Tahija, S. G. et al. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br. J. Ophthalmol. 98, 507\u2013512. https:\/\/doi.org\/10.1136\/bjophthalmol-2013-304109 (2014).","journal-title":"Br. J. Ophthalmol."},{"key":"82445_CR24","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.oret.2018.01.017","volume":"2","author":"R Roohipoor","year":"2018","unstructured":"Roohipoor, R. et al. Comparison of intravitreal bevacizumab and laser photocoagulation in the treatment of retinopathy of prematurity. Ophthalmol. Retin 2, 942\u2013948. https:\/\/doi.org\/10.1016\/j.oret.2018.01.017 (2018).","journal-title":"Ophthalmol. Retin"},{"key":"82445_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ajo.2018.09.039","volume":"198","author":"TA Chen","year":"2019","unstructured":"Chen, T. A. et al. A spectrum of regression following intravitreal bevacizumab in retinopathy of prematurity. Am. J. Ophthalmol. 198, 63\u201369. https:\/\/doi.org\/10.1016\/j.ajo.2018.09.039 (2019).","journal-title":"Am. J. Ophthalmol."},{"key":"82445_CR26","doi-asserted-by":"publisher","first-page":"100281","DOI":"10.1016\/j.xops.2023.100281","volume":"3","author":"XC Ling","year":"2023","unstructured":"Ling, X. C. et al. Persistent vascular anomalies in retinopathy of prematurity children: ultrawide-field fluorescein angiography findings until school age. Ophthalmol. Sci. 3, 100281. https:\/\/doi.org\/10.1016\/j.xops.2023.100281 (2023).","journal-title":"Ophthalmol. Sci."},{"key":"82445_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.4274\/tjo.galenos.2022.76436","volume":"53","author":"\u015e \u00d6zdek","year":"2023","unstructured":"\u00d6zdek, \u015e. et al. Avascular peripheral retina in infants. Turkish J. Ophthalmol. 53, 44\u201357. https:\/\/doi.org\/10.4274%2Ftjo.galenos.2022.76436 (2023).","journal-title":"Turkish J. Ophthalmol."},{"key":"82445_CR28","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/icu.0000000000000787","volume":"32","author":"E Chang","year":"2021","unstructured":"Chang, E. et al. Adult retinopathy of prematurity: treatment implications, long term sequelae, and management. Curr. Opin. Ophthalmol. 32, 489\u2013493. https:\/\/doi.org\/10.1097\/icu.0000000000000787 (2021).","journal-title":"Curr. Opin. Ophthalmol."},{"key":"82445_CR29","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","volume":"121","author":"D Lepore","year":"2014","unstructured":"Lepore, D. et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology 121, 2212\u20132219. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.015 (2014).","journal-title":"Ophthalmology"},{"key":"82445_CR30","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/iae.0000000000001581","volume":"38","author":"JM Garcia Gonzalez","year":"2018","unstructured":"Garcia Gonzalez, J. M. et al. Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity. Retina 38, 764\u2013772. https:\/\/doi.org\/10.1097\/iae.0000000000001581 (2018).","journal-title":"Retina"},{"key":"82445_CR31","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jaapos.2013.01.004","volume":"17","author":"S Ittiara","year":"2013","unstructured":"Ittiara, S. et al. Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab. J. AAPOS 17, 323\u2013325. https:\/\/doi.org\/10.1016\/j.jaapos.2013.01.004 (2013).","journal-title":"J. AAPOS"},{"key":"82445_CR32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3928\/01913913-20190501-01","volume":"56","author":"R Al-Taie","year":"2019","unstructured":"Al-Taie, R. et al. Persistent avascular retina in infants with a history of type 2 retinopathy of prematurity: to treat or not to treat? J. Pediatr. Ophthalmol. Strabismus 56, 222\u2013228. https:\/\/doi.org\/10.3928\/01913913-20190501-01 (2019).","journal-title":"J. Pediatr. Ophthalmol. Strabismus"},{"key":"82445_CR33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/14767058.2012.712313","volume":"25","author":"V Purcaro","year":"2012","unstructured":"Purcaro, V. et al. Fluorescein angiography and retinal vascular development in premature infants. J. Matern Fetal Neonatal Med. 25, 53\u201356. https:\/\/doi.org\/10.3109\/14767058.2012.712313 (2012).","journal-title":"J. Matern Fetal Neonatal Med."},{"key":"82445_CR34","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3928\/23258160-20180803-11","volume":"49","author":"L Golas","year":"2018","unstructured":"Golas, L. et al. Late ROP reactivation and retinal detachment in a teenager. Ophthalmic Surg. Lasers Imaging Retina 49, 625\u2013628. https:\/\/doi.org\/10.3928\/23258160-20180803-11 (2018).","journal-title":"Ophthalmic Surg. Lasers Imaging Retina"},{"key":"82445_CR35","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ajo.2012.06.010","volume":"155","author":"WC Wu","year":"2013","unstructured":"Wu, W. C. et al. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan. Am. J. Ophthalmol. 155, 150\u2013158e1. https:\/\/doi.org\/10.1016\/j.ajo.2012.06.010 (2013).","journal-title":"Am. J. Ophthalmol."},{"key":"82445_CR36","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/s0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl, A. et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet 394, 1551\u20131559. https:\/\/doi.org\/10.1016\/s0140-6736(19)31344-3 (2019).","journal-title":"Lancet"},{"key":"82445_CR37","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.survophthal.2024.02.005","volume":"69","author":"A Ortiz-Seller","year":"2024","unstructured":"Ortiz-Seller, A. et al. Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: a network meta-analysis. Surv. Ophthalmol. 69, 585\u2013605. https:\/\/doi.org\/10.1016\/j.survophthal.2024.02.005 (2024).","journal-title":"Surv. Ophthalmol."},{"key":"82445_CR38","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/iae.0b013e31822c290f","volume":"32","author":"MW Stewart","year":"2012","unstructured":"Stewart, M. W. et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 32, 434\u2013457. https:\/\/doi.org\/10.1097\/iae.0b013e31822c290f (2012).","journal-title":"Retina"},{"key":"82445_CR39","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00417-017-3878-4","volume":"256","author":"CY Huang","year":"2018","unstructured":"Huang, C. Y. et al. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Graefes Arch. Clin. Exp. Ophthalmol. 256, 479\u2013487. https:\/\/doi.org\/10.1007\/s00417-017-3878-4 (2018).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"82445_CR40","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.ophtha.2022.06.042","volume":"129","author":"E Chang","year":"2022","unstructured":"Chang, E. et al. A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of prematurity. Ophthalmology 129, 1389\u20131401. https:\/\/doi.org\/10.1016\/j.ophtha.2022.06.042 (2022).","journal-title":"Ophthalmology"},{"key":"82445_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","volume":"257","author":"EA Sukgen","year":"2019","unstructured":"Sukgen, E. A. et al. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity. Graefes Arch. Clin. Exp. Ophthalmol. 257, 49\u201355. https:\/\/doi.org\/10.1007\/s00417-018-4168-5 (2019).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"82445_CR42","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.preteyeres.2018.10.006","volume":"69","author":"T Van Bergen","year":"2019","unstructured":"Van Bergen, T. et al. The role of placental growth factor (PlGF) and its receptor system in retinal vascular diseases. Prog Retin Eye Res. 69, 116\u2013136. https:\/\/doi.org\/10.1016\/j.preteyeres.2018.10.006 (2019).","journal-title":"Prog Retin Eye Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82445-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82445-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82445-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T14:03:22Z","timestamp":1735394602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82445-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["82445"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-82445-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5118785\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,28]]},"assertion":[{"value":"19 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31097"}}